400 related articles for article (PubMed ID: 22923494)
21. Epigenetic-based treatments emphasize the biologic differences of core-binding factor acute myeloid leukemias.
Serrano E; Carnicer MJ; Lasa A; Orantes V; Pena J; Brunet S; Aventín A; Sierra J; Nomdedéu JF
Leuk Res; 2008 Jun; 32(6):944-53. PubMed ID: 18206229
[TBL] [Abstract][Full Text] [Related]
22. The thrombopoietin/MPL/Bcl-xL pathway is essential for survival and self-renewal in human preleukemia induced by AML1-ETO.
Chou FS; Griesinger A; Wunderlich M; Lin S; Link KA; Shrestha M; Goyama S; Mizukawa B; Shen S; Marcucci G; Mulloy JC
Blood; 2012 Jul; 120(4):709-19. PubMed ID: 22337712
[TBL] [Abstract][Full Text] [Related]
23. Cooperation between constitutively activated c-Kit signaling and leukemogenic transcription factors in the determination of the leukemic phenotype in murine hematopoietic stem cells.
Zheng X; Oancea C; Henschler R; Ruthardt M
Int J Oncol; 2009 Jun; 34(6):1521-31. PubMed ID: 19424569
[TBL] [Abstract][Full Text] [Related]
24. Identification of AML1-ETO modulators by chemical genomics.
Corsello SM; Roti G; Ross KN; Chow KT; Galinsky I; DeAngelo DJ; Stone RM; Kung AL; Golub TR; Stegmaier K
Blood; 2009 Jun; 113(24):6193-205. PubMed ID: 19377049
[TBL] [Abstract][Full Text] [Related]
25. Epigenetic silencing of miR564 contributes to the leukemogenesis of t(8;21) acute myeloid leukemia.
Yang E; Guan W; Gong D; Gao X; Han C; Zhang J; Wang H; Wang M; Li Y; Yu L
Clin Sci (Lond); 2020 Dec; 134(23):3079-3091. PubMed ID: 33201243
[TBL] [Abstract][Full Text] [Related]
26. Epigenetic silencing of microRNA-193a contributes to leukemogenesis in t(8;21) acute myeloid leukemia by activating the PTEN/PI3K signal pathway.
Li Y; Gao L; Luo X; Wang L; Gao X; Wang W; Sun J; Dou L; Li J; Xu C; Wang L; Zhou M; Jiang M; Zhou J; Caligiuri MA; Nervi C; Bloomfield CD; Marcucci G; Yu L
Blood; 2013 Jan; 121(3):499-509. PubMed ID: 23223432
[TBL] [Abstract][Full Text] [Related]
27. PML-RARalpha/RXR Alters the Epigenetic Landscape in Acute Promyelocytic Leukemia.
Martens JH; Brinkman AB; Simmer F; Francoijs KJ; Nebbioso A; Ferrara F; Altucci L; Stunnenberg HG
Cancer Cell; 2010 Feb; 17(2):173-85. PubMed ID: 20159609
[TBL] [Abstract][Full Text] [Related]
28. Heterochromatic gene repression of the retinoic acid pathway in acute myeloid leukemia.
Fazi F; Zardo G; Gelmetti V; Travaglini L; Ciolfi A; Di Croce L; Rosa A; Bozzoni I; Grignani F; Lo-Coco F; Pelicci PG; Nervi C
Blood; 2007 May; 109(10):4432-40. PubMed ID: 17244680
[TBL] [Abstract][Full Text] [Related]
29. AML1/ETO cooperates with HIF1α to promote leukemogenesis through DNMT3a transactivation.
Gao XN; Yan F; Lin J; Gao L; Lu XL; Wei SC; Shen N; Pang JX; Ning QY; Komeno Y; Deng AL; Xu YH; Shi JL; Li YH; Zhang DE; Nervi C; Liu SJ; Yu L
Leukemia; 2015 Aug; 29(8):1730-40. PubMed ID: 25727291
[TBL] [Abstract][Full Text] [Related]
30. Co-expression of AML1-ETO and PML-RARa following treatment of de novo acute myeloid leukemia with AML1-ETO.
Zhang S; Zhou W; Li Y; Yu S; Xue M; Qiao Y; Jian J; Liu B; Wang D
Leuk Lymphoma; 2019 May; 60(5):1316-1319. PubMed ID: 30328750
[No Abstract] [Full Text] [Related]
31. Histone deacetylase 3 preferentially binds and collaborates with the transcription factor RUNX1 to repress AML1-ETO-dependent transcription in t(8;21) AML.
Guo C; Li J; Steinauer N; Wong M; Wu B; Dickson A; Kalkum M; Zhang J
J Biol Chem; 2020 Mar; 295(13):4212-4223. PubMed ID: 32071087
[TBL] [Abstract][Full Text] [Related]
32. The leukemogenicity of AML1-ETO is dependent on site-specific lysine acetylation.
Wang L; Gural A; Sun XJ; Zhao X; Perna F; Huang G; Hatlen MA; Vu L; Liu F; Xu H; Asai T; Xu H; Deblasio T; Menendez S; Voza F; Jiang Y; Cole PA; Zhang J; Melnick A; Roeder RG; Nimer SD
Science; 2011 Aug; 333(6043):765-9. PubMed ID: 21764752
[TBL] [Abstract][Full Text] [Related]
33. The leukemogenic t(8;21) fusion protein AML1-ETO controls rRNA genes and associates with nucleolar-organizing regions at mitotic chromosomes.
Bakshi R; Zaidi SK; Pande S; Hassan MQ; Young DW; Montecino M; Lian JB; van Wijnen AJ; Stein JL; Stein GS
J Cell Sci; 2008 Dec; 121(Pt 23):3981-90. PubMed ID: 19001502
[TBL] [Abstract][Full Text] [Related]
34. Time- and residue-specific differences in histone acetylation induced by VPA and SAHA in AML1/ETO-positive leukemia cells.
Barbetti V; Gozzini A; Cheloni G; Marzi I; Fabiani E; Santini V; Dello Sbarba P; Rovida E
Epigenetics; 2013 Feb; 8(2):210-9. PubMed ID: 23321683
[TBL] [Abstract][Full Text] [Related]
35. MEIS2 Is an Oncogenic Partner in AML1-ETO-Positive AML.
Vegi NM; Klappacher J; Oswald F; Mulaw MA; Mandoli A; Thiel VN; Bamezai S; Feder K; Martens JHA; Rawat VPS; Mandal T; Quintanilla-Martinez L; Spiekermann K; Hiddemann W; Döhner K; Döhner H; Stunnenberg HG; Feuring-Buske M; Buske C
Cell Rep; 2016 Jul; 16(2):498-507. PubMed ID: 27346355
[TBL] [Abstract][Full Text] [Related]
36. TAF1 plays a critical role in AML1-ETO driven leukemogenesis.
Xu Y; Man N; Karl D; Martinez C; Liu F; Sun J; Martinez CJ; Martin GM; Beckedorff F; Lai F; Yue J; Roisman A; Greenblatt S; Duffort S; Wang L; Sun X; Figueroa M; Shiekhattar R; Nimer S
Nat Commun; 2019 Oct; 10(1):4925. PubMed ID: 31664040
[TBL] [Abstract][Full Text] [Related]
37. AML1-ETO targets and suppresses cathepsin G, a serine protease, which is able to degrade AML1-ETO in t(8;21) acute myeloid leukemia.
Jin W; Wu K; Li YZ; Yang WT; Zou B; Zhang F; Zhang J; Wang KK
Oncogene; 2013 Apr; 32(15):1978-87. PubMed ID: 22641217
[TBL] [Abstract][Full Text] [Related]
38. UBASH3B/Sts-1-CBL axis regulates myeloid proliferation in human preleukemia induced by AML1-ETO.
Goyama S; Schibler J; Gasilina A; Shrestha M; Lin S; Link KA; Chen J; Whitman SP; Bloomfield CD; Nicolet D; Assi SA; Ptasinska A; Heidenreich O; Bonifer C; Kitamura T; Nassar NN; Mulloy JC
Leukemia; 2016 Mar; 30(3):728-39. PubMed ID: 26449661
[TBL] [Abstract][Full Text] [Related]
39. Redistribution of H3K27me3 and acetylated histone H4 upon exposure to azacitidine and decitabine results in de-repression of the AML1/ETO target gene IL3.
Buchi F; Masala E; Rossi A; Valencia A; Spinelli E; Sanna A; Gozzini A; Santini V
Epigenetics; 2014 Mar; 9(3):387-95. PubMed ID: 24300456
[TBL] [Abstract][Full Text] [Related]
40. The Transcriptome Study of Subtype M2 Acute Myeloblastic Leukemia.
Wu AY; Yang HC; Lin CM; Wu BD; Qu QS; Zheng YH; Wei H; Mei XQ; Zeng ZH; Ma XD
Cell Biochem Biophys; 2015 Jul; 72(3):653-6. PubMed ID: 27352183
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
